Altimmune (ALT) Expected to Announce Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) will likely be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $0.0010 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

Altimmune Stock Performance

ALT stock opened at $4.52 on Tuesday. The stock’s 50 day simple moving average is $4.51 and its 200 day simple moving average is $4.25. Altimmune has a 12-month low of $2.90 and a 12-month high of $7.73. The firm has a market cap of $509.99 million, a P/E ratio of -4.22 and a beta of 0.09. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. Barclays initiated coverage on shares of Altimmune in a research note on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Citizens Jmp cut their target price on shares of Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a report on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Altimmune currently has an average rating of “Hold” and an average target price of $17.60.

Insiders Place Their Bets

In related news, Director John Gill acquired 12,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 23rd. The shares were acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares in the company, valued at $51,250. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jerome Benedict Durso acquired 12,500 shares of Altimmune stock in a transaction that occurred on Monday, December 22nd. The stock was bought at an average cost of $4.13 per share, with a total value of $51,625.00. Following the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,625. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 30,527 shares of company stock valued at $125,278 in the last quarter. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Altimmune

Institutional investors have recently made changes to their positions in the stock. Arax Advisory Partners boosted its holdings in shares of Altimmune by 99.7% in the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after acquiring an additional 4,076 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in Altimmune in the fourth quarter worth approximately $36,000. CreativeOne Wealth LLC bought a new position in Altimmune during the 4th quarter valued at $38,000. Victory Capital Management Inc. acquired a new position in shares of Altimmune during the 3rd quarter valued at $38,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after buying an additional 5,253 shares in the last quarter. 78.05% of the stock is owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.